Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
13.00
-0.09 (-0.69%)
May 26, 2026, 1:42 PM EDT - Market open

Atrium Therapeutics Stock Forecast

Stock Price Forecast

The 2 analysts with 12-month price forecasts for Atrium Therapeutics stock have an average target of $25, which predicts a 92.31% increase from the current stock price of 13.

Price Target: $25 (+92.31%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$25$25$25$25
Change+92.31%+92.31%+92.31%+92.31%

Analyst Ratings

The average analyst rating for Atrium Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingMar '26May '26
Strong Buy12
Buy00
Hold00
Sell00
Strong Sell00
Total12

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Leerink Partners
Leerink Partners
Buy
Initiates
$25
BuyInitiates$25+92.31%May 15, 2026
Wells Fargo
Wells Fargo
Buy
Initiates
$25
BuyInitiates$25+92.31%Mar 10, 2026

Financial Forecast

Revenue This Year
8.08M
from 18.62M
Decreased by -56.60%
Revenue Next Year
8.08M
from 8.08M
EPS This Year
-4.18
from -3.19
EPS Next Year
-4.67
from -4.18
Fiscal YearFY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
9.76M10.90M18.62M8.08M8.08M
Revenue Growth
-11.60%70.85%-56.60%-
EPS
---3.19-4.18-4.67
EPS Growth
-----
Forward PE
-----
No. Analysts
---22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20262027
High8.4M8.4M
Avg8.1M8.1M
Low7.8M7.8M

Revenue Growth

Revenue Growth20262027
High
-54.9%
4.0%
Avg
-56.6%
-
Low
-57.9%
-3.0%

EPS Forecast

EPS20262027
High-4.35-4.85
Avg-4.18-4.67
Low-4.06-4.53

EPS Growth

EPS Growth20262027
High--
Avg--
Low--
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.